In clear cell renal cell carcinoma (ccRCC), METTL3 and METTL14 constitute a risk signature for use in prognostics, because they are significantly enriched in cancer-related pathways, including the Wnt/β-catenin signaling pathway [40]. Here, METTL3 is linked to cancer.